Biotech Startups
10,028 companies tagged Biotech, with their investors and founders.
NuvOx Therapeutics is a clinical-stage pharmaceutical company developing NanO₂, an oxygen therapeutic drug intended to improve oxygen flow from lungs to blood and to tissue in order to reverse tissue hypoxia. Its clinical programs target indications including glioblastoma (as a radio sensitizer), stroke, and respiratory distress.
0 investors
NV Therapeutics develops non-viral gene therapies designed to be safe, effective, and scalable. The company targets a new generation of genetic treatments for disease.
0 investors
NVIGEN develops multifunctional, biodegradable magnetic nanoparticles (nanobeads) and related assays for the biomedical research and diagnostics community, supporting applications such as NGS sample preparation, DNA/RNA/protein/exosome/cell isolation, liquid-biopsy immunodiagnostics, drug delivery, and cell therapy. It also offers precision-medicine biomarker profiling and single-cell RNA sequencing products for cancer detection and personalized therapy.
0 investors
0 investors
NXT Biomedical is a medical device incubator that develops and spins out startups building clinical medical technologies aimed at addressing unmet needs and reducing healthcare costs. It plans to invest $25 million over five years to create five to eight companies.
0 investors
0 investors
Objective Biotechnology develops neurotechnology tools for cortex-wide optical access and neural recordings in unrestrained rodent models, along with automated microinjection systems for large-scale genetic manipulation and embryo microinjection. Its products serve researchers working with biological systems.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
OcuDyne develops an investigational ophthalmic device called OPTiC that is currently undergoing clinical trials in the United States. The company operates in the medical device and healthcare sector, focused on eye care applications.
0 investors
0 investors
Ocugenix is a biotechnology company developing ophthalmology therapeutics based on NIH-funded research into the molecular mechanisms of wound healing and cellular response, originating from a research team at the University of Pittsburgh Medical Center. Its focus areas include eye diseases such as glaucoma and retinal conditions.
0 investors
0 investors
Oisín Biotechnologies develops non-viral genetic therapies built on its Fusogenix Proteo-Lipid Vehicle (PLV) delivery platform, which delivers DNA and RNA payloads to tissues throughout the body and allows repeat dosing. Its pipeline targets the biology of aging, with programs in targeted fat removal, muscle building, and longevity biology across aesthetic and longevity medicine.
0 investors
Okogen is a clinical-stage ophthalmic pharmaceutical company developing a treatment for acute infectious conjunctivitis, covering both bacterial and viral forms. Its lead product is in clinical trials as a single treatment for all forms of the condition.
0 investors
0 investors
Oleander Medical Technologies develops Targeted Osmotic Lysis, a medical technology approach for treating cancer in animals. The company works with veterinary hospitals and regulatory consultants to advance its therapeutic platform.
0 investors
0 investors
Omeza is an ocean biotechnology company developing marine-based regenerative wound-care products, including its FDA-cleared OCM wound matrix made from cold-water fish peptides, omega fatty acids, and plant-derived lipids, to treat chronic, hard-to-heal wounds such as diabetic foot ulcers and venous leg ulcers in adults. The commercial-stage company serves the U.S. advanced wound care market and markets its products to clinical care sites.
0 investors
OmniAb develops transgenic animal platforms engineered to generate human antibodies for therapeutic drug discovery, serving biopharmaceutical researchers and drug developers.
0 investors
0 investors